Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13119MR)

This product GTTS-WQ13119MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13119MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14284MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ7861MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ14199MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ458MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ13401MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ11996MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ4487MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ2484MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW